Position in CELC
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$9,559,909
-$167,334 QoQ
Shares Held
83,756
-14.1% QoQ
Ownership
0.172%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026TD Asset Management Inc holds $1,314,505,240 across 121 Biotechnology names. CELC ranks #32 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
350,923 | $271,137,146 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
228,195 | $101,898,194 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
281,848 | $93,255,047 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,168,666 | $75,530,883 | |
| 5 | ARGX |
Argenx SE
|
80,824 | $59,021,726 | |
| 6 | ASND |
Ascendis Pharma A/S
|
217,992 | $49,861,310 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
529,954 | $39,794,245 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
317,811 | $30,907,119 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,559,909 | 83,756 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $9,727,243 | 97,526 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $3,596,122 | 72,796 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||